Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...

Stock futures are little changed as investors aim for a third-straight winning session. Google is the latest tech giant to ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Eli Lilly stock rose after the drugmaker posted quarterly earnings that beat Wall Street expectations, and issued upbeat 2025 guidance. Fourth-quarter adjusted earnings came in at $5.32 a share, above ...

Tesla sales careened lower in Germany in January, as sales of the electric vehicle company headed by Elon Musk tumble across Europe. The TV spot marks the artificial-intelligence company's biggest ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

We disagree as this is an AI Arms Race and Alphabet is making the right moves at the right time. While this quarter was not a ...

Alphabet revenue misses expectations, Robinhood Markets says Super Bowl bets are off, and more news to start your day.